Cellumed Signs Technology Development Contract for Manufacturing Specific Enzymes for mRNA Vaccines

[Asia Economy Reporter Minji Lee] Cellumed announced on the 13th that it has signed a technology development outsourcing contract with the German company ARTES Biotechnology GmbH for the production of specific enzymes related to mRNA vaccines.

The company stated, "Cellumed intends to outsource the development of two types of mRNA vaccine production enzymes through ARTES Biotechnology GmbH," and added, "After completing the outsourced development, we plan to transfer the technology and outsource production (CMO) to Richter Helm Biologics, a partner company of ARTES."

The advance payment that Cellumed must provide to the company is 1.31 billion KRW, with milestones totaling 5.02 billion KRW, making the total contract amount approximately 15.8% of its equity capital.